Molibresib

DB16239InvestigationalSmall molecule

Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory...

Formula / weight: C₂₂H₂₂ClN₅O₂ · 423.9 g/mol (avg)
Also known as: Bet inhibitor gsk525762
Code names: GSK-525762 · GSK-525762A · I-BET 762

Resolves to

Compound

UNII5QIO6SRZ2RCAS1260907-17-2ChEMBLCHEMBL1232461ChEBI95082

Structure

InChIKeyAAAQFGUYHFJNHI-SFHVURJKSA-NSMILESCCNC(=O)C[C@@H]1N=C(C2=CC=C(Cl)C=C2)C2=CC(OC)=CC=C2N2C(C)=NN=C12

Targets

O60885BRD4

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Molibresib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account